Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Extension in Pediatric SBS
NCT02949362Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2016
- Primary completion
- Jul 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Number of Participants With Adverse Events (AEs) at Week 168, Change From Baseline in Height for Age Z-score at Week 168 and 6 more. Started Dec 2016; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02949362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949362.